ofloxacin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibacterials, nalidixic acid derivatives 1981 82419-36-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • gailuoxian
  • ofloxacine
  • oxaldin
  • prifloxcin
  • prifloxin
  • ofloxacin
  • ofloxacin hydrochloride
  • ofloxacin HCl
A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
  • Molecular weight: 361.37
  • Formula: C18H20FN3O4
  • CLOGP: -0.26
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 1
  • TPSA: 73.32
  • ALOGS: -2.40
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O
0.40 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 3.54 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 64 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 31.62 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 1.60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.75 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 8.90 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 28, 1990 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxic anterior segment syndrome 95.93 16.14 25 6448 1540 50597111
Endophthalmitis 84.78 16.14 26 6447 2890 50595761
Drug reaction with eosinophilia and systemic symptoms 69.47 16.14 44 6429 28380 50570271
Hypopyon 67.80 16.14 16 6457 653 50597998
Acute kidney injury 65.68 16.14 110 6363 227948 50370703
Cholestasis 63.77 16.14 40 6433 25361 50573290
Corneal perforation 62.03 16.14 14 6459 468 50598183
Corneal oedema 51.75 16.14 15 6458 1372 50597279
Drug resistance 50.44 16.14 31 6442 18958 50579693
Eye pain 47.94 16.14 35 6438 28414 50570237
Rash maculo-papular 47.69 16.14 34 6439 26607 50572044
Cataract 43.60 16.14 41 6432 47259 50551392
Corneal deposits 43.49 16.14 9 6464 198 50598453
Corneal erosion 41.98 16.14 9 6464 236 50598415
Eosinophilia 38.53 16.14 26 6447 18626 50580025
Hepatic cytolysis 37.33 16.14 19 6454 8084 50590567
Tendon pain 36.85 16.14 14 6459 2964 50595687
Psychotic disorder due to a general medical condition 36.74 16.14 8 6465 226 50598425
Agranulocytosis 35.29 16.14 26 6447 21395 50577256
Renal necrosis 33.78 16.14 6 6467 56 50598595
Drug hypersensitivity 32.07 16.14 87 6386 250923 50347728
Gingival ulceration 31.16 16.14 9 6464 813 50597838
Retinal pigment epithelial tear 30.87 16.14 7 6466 239 50598412
Acute generalised exanthematous pustulosis 30.05 16.14 17 6456 8921 50589730
Confusional state 29.52 16.14 70 6403 185858 50412793
Anuria 26.44 16.14 17 6456 11227 50587424
Periodontal disease 25.77 16.14 9 6464 1501 50597150
Face oedema 25.72 16.14 20 6453 17819 50580832
Ulcerative keratitis 25.42 16.14 10 6463 2323 50596328
Keratitis fungal 24.91 16.14 5 6468 94 50598557
Tendonitis 24.68 16.14 19 6454 16686 50581965
International normalised ratio increased 24.67 16.14 29 6444 43123 50555528
Thrombocytopenia 24.66 16.14 52 6421 127621 50471030
Eye irritation 24.24 16.14 19 6454 17121 50581530
Hyperthermia 24.16 16.14 14 6459 7682 50590969
Corneal infiltrates 23.78 16.14 5 6468 119 50598532
Visual acuity reduced 23.59 16.14 20 6453 20119 50578532
Hepatitis 22.92 16.14 24 6449 31429 50567222
Reversible cerebral vasoconstriction syndrome 22.80 16.14 9 6464 2110 50596541
Periodontitis 22.78 16.14 10 6463 3059 50595592
Tendon rupture 22.44 16.14 13 6460 7131 50591520
Visual impairment 22.37 16.14 35 6438 68240 50530411
Pyelonephritis 22.03 16.14 17 6456 14972 50583679
Keratolysis exfoliativa acquired 21.82 16.14 3 6470 3 50598648
Necrosis 21.50 16.14 11 6462 4725 50593926
Anterior chamber cell 21.39 16.14 6 6467 488 50598163
Hepatitis acute 21.14 16.14 13 6460 7948 50590703
Hepatocellular injury 21.09 16.14 21 6452 25926 50572725
Toxic epidermal necrolysis 20.88 16.14 19 6454 20973 50577678
Tendon disorder 20.30 16.14 11 6462 5311 50593340
Drug interaction 19.54 16.14 63 6410 199558 50399093
Mucosal erosion 19.42 16.14 7 6466 1280 50597371
Corneal epithelium defect 18.84 16.14 5 6468 330 50598321
Type I hypersensitivity 18.44 16.14 8 6465 2377 50596274
Shock haemorrhagic 18.11 16.14 12 6461 8332 50590319
Vitritis 17.96 16.14 6 6467 876 50597775
Aortic dissection 17.92 16.14 7 6466 1596 50597055
Renal failure 17.82 16.14 41 6432 106592 50492059
Clostridium difficile colitis 17.53 16.14 16 6457 17726 50580925
Metamorphopsia 17.39 16.14 6 6467 965 50597686
Intraocular pressure increased 17.23 16.14 10 6463 5506 50593145
Central nervous system immune reconstitution inflammatory response 16.99 16.14 3 6470 27 50598624
Pathogen resistance 16.94 16.14 10 6463 5679 50592972
Eye infection 16.81 16.14 12 6461 9394 50589257
Factor V inhibition 16.74 16.14 4 6469 172 50598479
Encephalopathy 16.58 16.14 21 6452 33690 50564961
Cardioactive drug level increased 16.48 16.14 7 6466 1977 50596674
Extensor plantar response 16.38 16.14 6 6467 1148 50597503
Hepatitis cholestatic 16.27 16.14 10 6463 6107 50592544

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 132.26 15.95 81 6604 27911 29539931
Tendonitis 79.80 15.95 38 6647 7923 29559919
Type 2 lepra reaction 79.39 15.95 16 6669 167 29567675
Cholestasis 69.90 15.95 51 6634 23411 29544431
Hepatocellular injury 67.45 15.95 48 6637 21195 29546647
Toxic epidermal necrolysis 62.24 15.95 43 6642 18110 29549732
Rash maculo-papular 61.70 15.95 48 6637 24241 29543601
Keratitis fungal 55.56 15.95 10 6675 53 29567789
Ulcerative keratitis 54.79 15.95 18 6667 1405 29566437
Eosinophilia 52.42 15.95 42 6643 22119 29545723
Corneal oedema 50.31 15.95 16 6669 1126 29566716
Tendon pain 48.38 15.95 19 6666 2481 29565361
Eye pain 45.81 15.95 30 6655 11565 29556277
Agranulocytosis 44.84 15.95 37 6648 20303 29547539
Hyperacusis 43.60 15.95 13 6672 737 29567105
Tendon rupture 42.46 15.95 23 6662 6272 29561570
Acute kidney injury 40.89 15.95 142 6543 265125 29302717
Corneal deposits 38.88 15.95 9 6676 187 29567655
Visual acuity reduced 36.90 15.95 29 6656 14847 29552995
Endophthalmitis 36.07 15.95 16 6669 2832 29565010
Laryngeal haematoma 35.18 15.95 8 6677 153 29567689
Motion sickness 33.91 15.95 8 6677 181 29567661
Skin hyperpigmentation 32.81 15.95 15 6670 2849 29564993
Distal intestinal obstruction syndrome 31.10 15.95 8 6677 261 29567581
Corneal opacity 30.29 15.95 9 6676 504 29567338
Tendon disorder 28.45 15.95 13 6672 2465 29565377
Purpura 27.31 15.95 20 6665 9212 29558630
Retinal pigment epithelial tear 26.69 15.95 7 6678 247 29567595
Anterior chamber cell 25.77 15.95 7 6678 283 29567559
Chronic fatigue syndrome 25.65 15.95 7 6678 288 29567554
Vascular purpura 24.83 15.95 10 6675 1393 29566449
Haemolytic anaemia 24.74 15.95 19 6666 9400 29558442
Upper airway obstruction 24.55 15.95 8 6677 608 29567234
Hepatic cytolysis 24.51 15.95 18 6667 8329 29559513
Corneal epithelium defect 24.19 15.95 7 6678 357 29567485
Eye inflammation 23.00 15.95 10 6675 1686 29566156
Hyperthermia 22.55 15.95 18 6667 9412 29558430
Tendon discomfort 22.12 15.95 6 6679 241 29567601
Dysaesthesia 21.19 15.95 10 6675 2040 29565802
Corneal thinning 20.49 15.95 5 6680 131 29567711
Toxic anterior segment syndrome 20.49 15.95 8 6677 1028 29566814
Intraocular pressure increased 20.41 15.95 13 6672 4776 29563066
Hypopyon 20.19 15.95 6 6679 336 29567506
Red blood cell vacuolisation 20.11 15.95 3 6682 3 29567839
Fibrin 19.65 15.95 3 6682 4 29567838
Muscle contractions involuntary 19.64 15.95 9 6676 1718 29566124
Corneal perforation 19.30 15.95 5 6680 168 29567674
Pudendal canal syndrome 18.89 15.95 3 6682 6 29567836
Corneal disorder 18.63 15.95 7 6678 810 29567032
Neuralgia 18.35 15.95 17 6668 10857 29556985
Tinnitus 18.24 15.95 20 6665 15594 29552248
Prostatitis 18.17 15.95 12 6673 4685 29563157
Sideroblastic anaemia 18.15 15.95 5 6680 213 29567629
Intra-abdominal haemorrhage 17.98 15.95 9 6676 2086 29565756
Haematoma 17.76 15.95 24 6661 23188 29544654
Drug resistance 17.60 15.95 23 6662 21517 29546325
Tuberculoma of central nervous system 17.51 15.95 5 6680 243 29567599
Neuropathy peripheral 17.50 15.95 45 6640 70982 29496860
Atrophy 17.17 15.95 7 6678 1006 29566836
Cataract 16.92 15.95 23 6662 22355 29545487
Vasculitis necrotising 16.83 15.95 6 6679 599 29567243
Immune reconstitution inflammatory syndrome 16.78 15.95 14 6671 7788 29560054
Oral candidiasis 16.64 15.95 16 6669 10706 29557136
Rash morbilliform 16.51 15.95 9 6676 2484 29565358
Death 16.37 15.95 33 6652 342051 29225791

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 187.51 14.16 120 11905 54097 64432610
Cholestasis 123.01 14.16 86 11939 44786 64441921
Toxic anterior segment syndrome 108.89 14.16 33 11992 2406 64484301
Rash maculo-papular 105.86 14.16 80 11945 46946 64439761
Endophthalmitis 104.93 14.16 39 11986 5326 64481381
Corneal oedema 97.36 14.16 30 11995 2313 64484394
Acute kidney injury 94.26 14.16 237 11788 449003 64037704
Type 2 lepra reaction 92.41 14.16 18 12007 192 64486515
Tendonitis 85.56 14.16 51 11974 20231 64466476
Eosinophilia 81.77 14.16 63 11962 38013 64448694
Hepatocellular injury 78.36 14.16 66 11959 45169 64441538
Toxic epidermal necrolysis 76.56 14.16 60 11965 37106 64449601
Corneal perforation 76.22 14.16 19 12006 665 64486042
Hypopyon 73.14 14.16 20 12005 1009 64485698
Corneal deposits 70.93 14.16 16 12009 361 64486346
Tendon pain 69.07 14.16 28 11997 4820 64481887
Agranulocytosis 68.74 14.16 57 11968 38172 64448535
Ulcerative keratitis 58.68 14.16 22 12003 3075 64483632
Hepatic cytolysis 58.40 14.16 35 11990 14014 64472693
Retinal pigment epithelial tear 58.30 14.16 14 12011 418 64486289
Keratitis fungal 58.26 14.16 12 12013 173 64486534
Eye pain 54.46 14.16 46 11979 31579 64455128
Drug resistance 54.26 14.16 48 11977 35054 64451653
Tendon rupture 53.17 14.16 30 11995 10737 64475970
Hyperthermia 45.39 14.16 31 11994 15519 64471188
Anterior chamber cell 44.86 14.16 13 12012 811 64485896
Visual acuity reduced 39.74 14.16 36 11989 27105 64459602
Corneal opacity 39.35 14.16 12 12013 893 64485814
Tendon disorder 37.79 14.16 20 12005 6312 64480395
Psychotic disorder due to a general medical condition 37.37 14.16 9 12016 272 64486435
Hepatitis 36.90 14.16 44 11981 45538 64441169
Laryngeal haematoma 36.52 14.16 8 12017 157 64486550
Thrombocytopenia 35.67 14.16 107 11918 223694 64263013
Haemolytic anaemia 35.41 14.16 27 11998 16026 64470681
International normalised ratio increased 34.85 14.16 57 11968 79110 64407597
Hyperacusis 33.90 14.16 13 12012 1932 64484775
Vascular purpura 33.81 14.16 14 12011 2542 64484165
Corneal epithelium defect 33.74 14.16 10 12015 675 64486032
Keratolysis exfoliativa acquired 33.16 14.16 5 12020 8 64486699
Intraocular pressure increased 32.74 14.16 20 12005 8282 64478425
Corneal infiltrates 32.17 14.16 8 12017 277 64486430
Acute generalised exanthematous pustulosis 31.79 14.16 24 12001 14034 64472673
Skin hyperpigmentation 31.66 14.16 18 12007 6533 64480174
Cataract 29.78 14.16 42 11983 51220 64435487
Confusional state 28.50 14.16 110 11915 261034 64225673
Renal necrosis 27.78 14.16 7 12018 256 64486451
Corneal erosion 26.80 14.16 7 12018 296 64486411
Distal intestinal obstruction syndrome 25.79 14.16 8 12017 630 64486077
Corneal graft rejection 25.78 14.16 5 12020 52 64486655
Purpura 25.49 14.16 23 12002 17223 64469484
Eye irritation 25.13 14.16 22 12003 15834 64470873
Periodontal disease 24.89 14.16 10 12015 1681 64485026
Prothrombin time ratio decreased 24.28 14.16 8 12017 765 64485942
Motion sickness 24.23 14.16 8 12017 770 64485937
Ocular hyperaemia 23.78 14.16 25 12000 22539 64464168
Gingival ulceration 23.53 14.16 8 12017 842 64485865
Toxic skin eruption 23.30 14.16 23 12002 19261 64467446
Fibrin 22.72 14.16 4 12021 23 64486684
Eye inflammation 22.55 14.16 13 12012 4844 64481863
Vitritis 22.34 14.16 9 12016 1524 64485183
Dizziness 21.81 14.16 29 11996 430134 64056573
Reversible cerebral vasoconstriction syndrome 21.75 14.16 10 12015 2332 64484375
Keratitis 21.54 14.16 11 12014 3226 64483481
Hyperbilirubinaemia 21.47 14.16 23 12002 21182 64465525
Renal failure 21.01 14.16 78 11947 181610 64305097
Delusion of reference 20.96 14.16 5 12020 145 64486562
Chronic fatigue syndrome 20.87 14.16 8 12017 1187 64485520
Visual impairment 20.83 14.16 44 11981 74033 64412674
Corneal thinning 20.52 14.16 5 12020 159 64486548
Upper airway obstruction 20.47 14.16 8 12017 1250 64485457
Mucosal erosion 20.32 14.16 9 12016 1925 64484782
Hepatitis acute 20.07 14.16 18 12007 13371 64473336
Retinal oedema 20.02 14.16 7 12018 801 64485906
Corneal disorder 19.91 14.16 9 12016 2018 64484689
Red blood cell vacuolisation 19.82 14.16 3 12022 5 64486702
Rash morbilliform 19.29 14.16 12 12013 5129 64481578
Immune reconstitution inflammatory syndrome 19.16 14.16 17 12008 12453 64474254
Fatigue 18.81 14.16 74 11951 748656 63738051
Sideroblastic anaemia 18.69 14.16 5 12020 232 64486475
Pudendal canal syndrome 18.61 14.16 3 12022 9 64486698
Neuropathy peripheral 18.51 14.16 56 11969 117469 64369238
Tuberculoma of central nervous system 18.48 14.16 6 12019 548 64486159
Aortic dissection 18.08 14.16 10 12015 3442 64483265
Gastroenteritis staphylococcal 17.86 14.16 5 12020 275 64486432
Encephalopathy 17.79 14.16 36 11989 58783 64427924
Dermatitis exfoliative 17.70 14.16 15 12010 10337 64476370
Ecchymosis 17.45 14.16 17 12008 14005 64472702
Weight increased 17.44 14.16 9 12016 213339 64273368
Dysaesthesia 17.10 14.16 11 12014 4984 64481723
Eye infection 17.01 14.16 14 12011 9267 64477440
Vitreous floaters 16.94 14.16 12 12013 6361 64480346
Hepatosplenomegaly 16.42 14.16 11 12014 5332 64481375
Necrosis 16.40 14.16 13 12012 8158 64478549
Persecutory delusion 16.35 14.16 10 12015 4148 64482559
Gamma-glutamyltransferase increased 16.25 14.16 31 11994 48479 64438228
Toxicity to various agents 15.99 14.16 27 11998 363486 64123221
Muscle contractions involuntary 15.98 14.16 9 12016 3208 64483499
Anterior chamber flare 15.73 14.16 4 12021 152 64486555
Tendon discomfort 15.69 14.16 5 12020 430 64486277
Conjunctivitis 15.41 14.16 19 12006 20335 64466372
Dermatitis exfoliative generalised 15.41 14.16 11 12014 5905 64480802
Glaucoma 15.28 14.16 17 12008 16331 64470376
Prostatitis 15.02 14.16 9 12016 3597 64483110
Completed suicide 14.89 14.16 12 12013 224402 64262305
Haematoma 14.81 14.16 29 11996 46221 64440486
Vasculitis necrotising 14.61 14.16 6 12019 1066 64485641
Artery dissection 14.55 14.16 4 12021 206 64486501
Muscle atrophy 14.39 14.16 13 12012 9745 64476962
Metamorphopsia 14.30 14.16 6 12019 1126 64485581
Retinal vasculitis 14.22 14.16 6 12019 1141 64485566
Atrophy 14.22 14.16 7 12018 1900 64484807

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01MA01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
QUINOLONE ANTIBACTERIALS
Fluoroquinolones
ATC J01RA09 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
COMBINATIONS OF ANTIBACTERIALS
Combinations of antibacterials
ATC S01AE01 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFECTIVES
Fluoroquinolones
ATC S02AA16 SENSORY ORGANS
OTOLOGICALS
ANTIINFECTIVES
Antiinfectives
FDA CS M0023650 Quinolones
CHEBI has role CHEBI:35441 antiinfective agents
CHEBI has role CHEBI:36047 antibacterial drugs
CHEBI has role CHEBI:59517 DNA synthesis inhibitors
FDA EPC N0000175937 Quinolone Antimicrobial
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000892 Anti-Infective Agents, Urinary
MeSH PA D000970 Antineoplastic Agents
MeSH PA D065609 Cytochrome P-450 CYP1A2 Inhibitors
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances
MeSH PA D059005 Topoisomerase II Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Otitis externa indication 3135009
Typhoid fever indication 4834000 DOID:13258
Septicemia due to Escherichia coli indication 9323009
Prostatitis indication 9713002 DOID:14654
Infection due to Pseudomonas aeruginosa indication 11218009
Gonorrhea indication 15628003 DOID:7551
Enteric campylobacteriosis indication 18081009
Infectious diarrheal disease indication 19213003 DOID:13250
Infection of skin AND/OR subcutaneous tissue indication 19824006
Acute gonococcal cervicitis indication 20943002 DOID:10615
Staphylococcal pneumonia indication 22754005
Acute gonococcal urethritis indication 29864006
Acute bacterial peritonitis indication 31860008
Bronchitis indication 32398004 DOID:6132
Postoperative infection indication 33910007
Pneumonia due to Streptococcus indication 34020007
Shigellosis indication 36188001
Cystitis indication 38822007 DOID:1679
Pneumonia due to Pseudomonas indication 41381004
Gonorrhea of rectum indication 42746002
Pyelonephritis indication 45816000 DOID:11400
Pneumonia due to Mycoplasma pneumoniae indication 46970008
Lower respiratory tract infection indication 50417007
Pneumonia due to Escherichia coli indication 51530003
Bacterial pneumonia indication 53084003 DOID:874
Klebsiella cystitis indication 60867007
Acute gonococcal endometritis indication 65295003 DOID:7527
Acute maxillary sinusitis indication 68272006 DOID:2050
Urinary tract infectious disease indication 68566005
Haemophilus influenzae pneumonia indication 70036007
Infection due to Escherichia coli indication 71057007
Rhinoscleroma indication 72409005 DOID:11336
Abdominal abscess indication 75100008
Acute bacterial sinusitis indication 75498004
Nongonococcal urethritis indication 84619001
Infective otitis externa indication 86981007 DOID:9463
Chronic tubotympanic suppurative otitis media indication 87665008 DOID:14435
Infection of bone indication 111253001
Female genital tract infection indication 125585007
Infectious disease of abdomen indication 128070006
Bacterial conjunctivitis indication 128350005 DOID:9700
Infection due to Enterobacteriaceae indication 128945009
Urethritis due to Chlamydia trachomatis indication 179101003
Bacterial infection due to Klebsiella pneumoniae indication 186435004
Chlamydial pelvic inflammatory disease indication 188463006
Acute Moraxella catarrhalis bronchitis indication 195722003
Proteus pneumonia indication 195888009
Malignant otitis externa due to Pseudomonas aeruginosa indication 232230009
Acute bacterial bronchitis indication 233598009
Pneumonia indication 233604007 DOID:552
Pneumococcal pneumonia indication 233607000
Chlamydial pneumonia indication 233609002
Infective cystitis indication 236620008
Chancroid indication 266143009 DOID:13778
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Streptococcus pyogenes infection indication 302809008
Bacterial urinary infection indication 312124009
Infective otitis media indication 312218008
Infectious disorder of joint indication 363162000
Infection due to Staphylococcus aureus indication 406602003
Anthrax indication 409498004 DOID:7427
Acute osteomyelitis indication 409780002
Nosocomial pneumonia indication 425464007
Acute exacerbation of chronic bronchitis indication 425748003
Urinary tract infection caused by Klebsiella indication 369001000119100
Pseudomonas Aeruginosa Urinary Tract Infection indication
Enterobacter Pneumonia indication
Mixed Gonococcal and Chlamydia Infection of the Urethra indication
Complicated Bacteroides Peritonitis indication
Pseudomonas Aeruginosa Cystitis indication
Skin and Skin Structure Serratia Infection indication
Complicated Bacterial Peritonitis indication
Chlamydia Cervicitis indication
Haemophilus Influenzae Chronic Bronchitis indication
Complicated Skin and Skin Structure Proteus Infection indication
Streptococcus Pneumoniae Bronchitis indication
Moraxella Catarrhalis Chronic Bronchitis indication
Chronic Staphylococcus epidermidis Prostatitis indication
Pseudomonas Aeruginosa Osteomyelitis indication
Haemophilus Parainfluenzae Pneumonia indication
Enterobacter Osteomyelitis indication
Providencia Urinary Tract Infection indication
Nosocomial Pneumonia due to Serratia Marcescens indication
Pelvic Inflammatory Disease with Neisseria Gonorrhea indication
Complicated Proteus UTI indication
Chronic Bacterial Prostatitis indication
Gram-Negative Aerobic Bacillary Pneumonia indication
Proteus Prostatitis indication
Staphylococcus Epidermidis Skin and Skin Structure Infection indication
Complicated Skin and Skin Structure Enterococcus Faecalis Infection indication
Serratia Joint Infection indication
Skin and Skin Structure Morganella Morganii Infection indication
Complicated Urinary Tract Infections indication
Nosocomial Pneumonia due to Escherichia Coli indication
Skin and Skin Structure Citrobacter Infection indication
Skin and Skin Structure Pseudomonas Aeruginosa Infection indication
Synergy for Nosocomial Pneumonia due to Pseudomonas Aeruginosa indication
Chronic Enterococcus faecalis Prostatitis indication
Complicated Skin and Skin Structure Streptococcus Pyogenes Infection indication
Colorectal Surgery Infection Prevention indication
Bacterial Corneal Ulcer Infection indication
Legionella Pneumophila Pneumonia indication
Complicated E. Coli Peritonitis indication
Nosocomial Pneumonia due to Methicillin-Sensitive Staphylococcus Aureus indication
Mixed Gonococcal and Chlamydia Infection of the Cervix indication
Complicated Skin and Skin Structure Staphylococcus Aureus Infection indication
Serratia Urinary Tract Infection indication
Diarrhea due to E. Coli indication
Moraxella Catarrhalis Pneumonia indication
E. Coli Pyelonephritis indication
Serratia Osteomyelitis indication
Staphylococcus Epidermidis Urinary Tract Infection indication
E. Coli Cystitis indication
Enterobacter Cystitis indication
Chronic Escherichia coli Prostatitis indication
Complicated UTI with Pseudomonas Aeruginosa indication
Pseudomonas Aeruginosa Joint Infection indication
Citrobacter Urinary Tract Infection indication
Citrobacter Complicated UTI indication
Skin and Skin Structure Proteus Infection indication
Streptococcus Pneumoniae Chronic Bronchitis indication
Staphylococcus Aureus Otitis Externa indication
Klebsiella Nosocomial Pneumonia indication
Enterococcus Complicated UTI indication
Haemophilus Parainfluenzae Bronchitis indication
Citrobacter Cystitis indication
Enterococcus Urinary Tract Infection indication
Haemophilus Influenzae Bronchitis indication
Staphylococcus Saprophyticus Urinary Tract Infection indication
Staphylococcus Aureus Bronchitis indication
Morganella Morganii Urinary Tract Infection indication
Staphylococcus Cystitis indication
Complicated Klebsiella Peritonitis indication
Nosocomial Pneumonia due to Streptococcus Pneumoniae indication
Complicated Skin and Skin Structure Infection indication
Nosocomial Pneumonia due to Klebsiella Pneumoniae indication
EnterobacterJoint Infection indication
Nosocomial Pneumonia due to Haemophilus Influenzae indication
Skin and Skin Structure Providencia Infection indication
Proteus Cystitis indication
Vaginal Hysterectomy Infection Prevention indication
Inhalational anthrax off-label use 11389007
Traveler's diarrhea off-label use 11840006
Acute tuberculosis off-label use 25629007
Salmonella septicemia off-label use 49786009
Cutaneous anthrax off-label use 84980006 DOID:7426
Gastrointestinal anthrax off-label use 111798006 DOID:13386
Pulmonary tuberculosis off-label use 154283005 DOID:2957
Diverticulitis of gastrointestinal tract off-label use 271366000
Ventilator-acquired pneumonia off-label use 429271009
Diabetic Foot Infection off-label use
Prevention of Meningococcal Meningitis off-label use
Hallucinations contraindication 7011001
Achilles tendinitis contraindication 11654001
Agranulocytosis contraindication 17182001 DOID:12987
Lowered convulsive threshold contraindication 19260006
Torsades de pointes contraindication 31722008
Transplantation of heart contraindication 32413006
Dehydration contraindication 34095006
Tendinitis contraindication 34840004 DOID:971
Hypokalemia contraindication 43339004
Bradycardia contraindication 48867003
Hepatic failure contraindication 59927004
Transplant of kidney contraindication 70536003
Diabetes mellitus contraindication 73211009 DOID:9351
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Transplant of lung contraindication 88039007
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Prolonged QT interval contraindication 111975006
Pancytopenia contraindication 127034005 DOID:12450
Superimposed infection contraindication 193198003
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409
Drug-induced hepatitis contraindication 235876009
Rhabdomyolysis contraindication 240131006
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Peripheral nerve disease contraindication 302226006
Viral ear infection contraindication 312137007
Pseudomembranous enterocolitis contraindication 397683000
Myocardial ischemia contraindication 414795007 DOID:3393
Traumatic rupture of tendon contraindication 415749005
Congenital long QT syndrome contraindication 442917000
Severe Cerebral Arteriosclerosis contraindication
Tremors contraindication
Shoulder Tendonitis contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.12 acidic
pKa2 8.29 Basic
pKa3 1.12 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent serotonin transporter Transporter IC50 4.54 WOMBAT-PK
Muscarinic acetylcholine receptor M1 GPCR IC50 4.41 WOMBAT-PK
Histamine H3 receptor GPCR IC50 4.55 WOMBAT-PK
Gamma-aminobutyric acid receptor subunit alpha-2 Ion channel IC50 4.23 WOMBAT-PK
DNA gyrase subunit A Enzyme INHIBITOR IC50 5.28 WOMBAT-PK CHEMBL
DNA gyrase subunit B Enzyme WOMBAT-PK
Gag-Pro-Pol polyprotein Polyprotein IC50 4.82 WOMBAT-PK
GABA-A receptor; anion channel Ion channel IC50 4.96 CHEMBL
CAAX prenyl protease 1 Enzyme AC50 5.71 CHEMBL
Trypsin Enzyme AC50 5.03 CHEMBL

External reference:

IDSource
4019567 VUID
N0000147667 NUI
D00453 KEGG_DRUG
4019567 VANDF
CHEBI:7731 CHEBI
XED PDB_CHEM_ID
CHEMBL4 ChEMBL_ID
10918 IUPHAR_LIGAND_ID
5322 INN_ID
118120-51-7 SECONDARY_CAS_RN
DB01165 DRUGBANK_ID
A4P49JAZ9H UNII
4583 PUBCHEM_CID
7623 RXNORM
47400 MMSL
5197 MMSL
d00114 MMSL
003563 NDDF
004136 NDDF
387551000 SNOMEDCT_US
441553007 SNOMEDCT_US
96086002 SNOMEDCT_US
D015242 MESH_DESCRIPTOR_UI
C0028902 UMLSCUI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 0404-7189 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 24 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 0517-0760 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 22 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 0517-0761 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 22 sections
OCUFLOX HUMAN PRESCRIPTION DRUG LABEL 1 11980-779 SOLUTION/ DROPS 3 mg OPHTHALMIC NDA 22 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 13985-602 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 25 sections
OFLOXACIN HUMAN PRESCRIPTION DRUG LABEL 1 16590-175 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 10 sections
OFLOXACIN HUMAN PRESCRIPTION DRUG LABEL 1 16590-931 SOLUTION/ DROPS 3 mg AURICULAR (OTIC) ANDA 11 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 17478-713 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 23 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 21695-439 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 19 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 21695-881 SOLUTION/ DROPS 3 mg AURICULAR (OTIC) ANDA 23 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 24208-410 SOLUTION 3 mg AURICULAR (OTIC) ANDA 18 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 24208-434 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 20 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 33261-737 SOLUTION 3 mg AURICULAR (OTIC) ANDA 18 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 42254-257 SOLUTION 3 mg AURICULAR (OTIC) ANDA 18 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50090-0891 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 22 sections
Ofloxacin Otic HUMAN PRESCRIPTION DRUG LABEL 1 50090-1090 SOLUTION 3 mg AURICULAR (OTIC) ANDA 20 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50090-1346 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 22 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50090-1346 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 22 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50090-3836 SOLUTION/ DROPS 3 mg AURICULAR (OTIC) ANDA 23 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50090-5186 SOLUTION 3 mg OPHTHALMIC ANDA 21 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50090-5209 SOLUTION 3 mg OPHTHALMIC ANDA 21 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50090-5210 SOLUTION 3 mg OPHTHALMIC ANDA 21 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50090-5425 SOLUTION 3 mg OPHTHALMIC ANDA 13 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50090-5670 SOLUTION 3 mg AURICULAR (OTIC) ANDA 19 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50383-024 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 21 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50383-025 SOLUTION/ DROPS 3 mg AURICULAR (OTIC) ANDA 23 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50436-0713 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 22 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50436-6112 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 19 sections
ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 52959-763 SOLUTION 3 mg OPHTHALMIC ANDA 22 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 53002-1324 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 22 sections